HIGH QUALITY SCIENTIFIC CONTENT,  ONLINE OPEN ACCESS,  GLOBAL SCIENTIFIC AUDIENCE,  COST EFFECTIVE, ANY ONE CAN DOWNLOAD REPRINTS 
Spreading knowledge

Google Scholar

Google Scholar

Archives

Back 

HCV (HEPATITIS C VIRUS) DRUG DISCOVERY AIMED AT VIRAL ERADICATION. Gurpreet Karwal, Dinesh Kumar, Pooja Sharma, H.S.Rao

HCV (HEPATITIS C VIRUS) DRUG DISCOVERY AIMED AT VIRAL ERADICATION.

Gurpreet Karwal, Dinesh Kumar, Pooja Sharma, H.S.Rao

International Journal of Natural Product Science 2012: Spl Issue 1:196.

Abstract(RBIP-196)

Hepatitis C virus (HCV) causes significant morbidity and mortality worldwide with nearly 3% of the world population infected by this virus. Fortunately, this virus does not establish latency, and hence it may be possible to eradicate it. HCV is strongly associated with liver cirrhosis and hepatocellular carcinoma and is currently treated with pegylated interferon-α (peg-IFN-α) and ribavirin. Unfortunately, these limited treatment options often produce significant side effects, and currently, complete eradication of virus with combined drug modalities has not yet been achieved for the majority of chronically HCV-infected individuals. Restricted treatment options, lack of a universal cure for HCV and the link between chronic infection, liver cirrhosis and hepatocellular carcinoma necessitate design of novel drugs and treatment options. Understanding the relationship between the immune response, viral clearance and inhibition of viral replication with pharmacology-based design can ultimately allow for complete eradication of HCV. This review focuses upon significant novel preclinical and clinical specifically targeted antiviral therapy (STAT-C) drugs under development, highlights their mechanism of action, and discusses their impact on systemic viral loads and permanent cleared Although the current standard of care for chronic HCV infection, combination peg-IFN-α and ribavirin treatment, displays efficacy in ~80% of individuals infected with genotype 2 or 3, a blanket cure that is efficacious across all genotypes does not exist. In particular, less than 50% of individuals with genotype 1 – the most aggressive and prevalent strain in Americas, Europe, China and Japan – present with sustained virological response (SVR) of infection.
Attachments:
Time to create page: 0.15 seconds


Copyright © All rights reserved Science Instinct Publications sciipub.com